Emergent BioSolutions Inc. to Host Conference Call on Q4 and Full Year 2025 Financial Results

Emergent BioSolutions will host a conference call on February 26, 2026, to discuss its 2025 financial results.

Quiver AI Summary

Emergent BioSolutions Inc. will hold a conference call on February 26, 2026, at 5:00 pm ET to discuss its financial results for the fourth quarter and full year of 2025. Participants can join via a live webcast on the company's Investors page, or by registering in advance to access the call by telephone, where they will receive a confirmation email with details. A replay will also be available on the website afterward. Emergent BioSolutions focuses on delivering protective solutions for public health threats, and has been operating for over 25 years. For more information, interested parties can visit the company's website or connect on social media platforms.

Potential Positives

Emergent BioSolutions is proactively engaging with investors by hosting a conference call to discuss its financial results, demonstrating transparency and a commitment to stakeholder communication.
The release highlights the company's long-standing mission of protecting public health, reinforcing its reputation and mission-driven focus in the biopharmaceutical industry.
The inclusion of various health threats the company addresses showcases its extensive portfolio and operational significance in critical public health areas, which may enhance investor confidence.

Potential Negatives

The announcement of a conference call to discuss financial results may indicate that the company is facing scrutiny regarding its performance, which could raise concerns among investors.
There is no mention of any growth or positive milestones in the release, potentially signaling stagnation in the company's financial health or operations.
The need for advance registration for the conference call could be seen as a barrier for some investors, limiting accessibility and engagement with the company's leadership.

FAQ

When is the Emergent BioSolutions conference call?

The conference call will be held on Thursday, February 26, 2026, at 5:00 PM Eastern Time.

How can I access the conference call?

You can access the call live via webcast on Emergent's Investors page or register to join by telephone.

What will be discussed during the conference call?

The call will discuss Emergent BioSolutions' financial results for the fourth quarter and full year of 2025.

Is there a replay available for the conference call?

Yes, a replay of the call will be accessible from the Investors page of Emergent BioSolutions' website.

Who can I contact for investor inquiries?

For investor inquiries, you can contact Richard S. Lindahl, Executive Vice President and CFO, at [email protected].

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$EBS Insider Trading Activity

$EBS insiders have traded $EBS stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:

COLEEN GLESSNER (EVP, Quality & Ethics, and CPL) sold 30,608 shares for an estimated $306,080
RONALD RICHARD has made 0 purchases and 2 sales selling 21,984 shares for an estimated $263,077.
DONALD W DEGOLYER sold 17,801 shares for an estimated $187,622
SUJATA TYAGI DAYAL sold 8,552 shares for an estimated $85,520
KATHRYN C ZOON sold 7,086 shares for an estimated $62,852

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$EBS Revenue

$EBS had revenues of $9.1M in Q3 2025. This is a decrease of -9.0% from the same period in the prior year.

You can track EBS financials on Quiver Quantitative's EBS stock page.

$EBS Hedge Fund Activity

We have seen 91 institutional investors add shares of $EBS stock to their portfolio, and 93 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

STATE STREET CORP added 705,004 shares (+40.5%) to their portfolio in Q3 2025, for an estimated $6,218,135
MILLENNIUM MANAGEMENT LLC removed 677,608 shares (-89.7%) from their portfolio in Q3 2025, for an estimated $5,976,502
AQR CAPITAL MANAGEMENT LLC added 586,246 shares (+inf%) to their portfolio in Q3 2025, for an estimated $5,170,689
PACER ADVISORS, INC. removed 536,655 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $6,633,055
JAIN GLOBAL LLC added 508,707 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,486,795
CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. removed 354,306 shares (-31.3%) from their portfolio in Q4 2025, for an estimated $4,379,222
PALISADE CAPITAL MANAGEMENT, LP added 326,260 shares (+29.7%) to their portfolio in Q3 2025, for an estimated $2,877,613

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$EBS Analyst Ratings

Wall Street analysts have issued reports on $EBS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 12/16/2025

To track analyst ratings and price targets for $EBS, check out Quiver Quantitative's $EBS forecast page.

Full Release

GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025.

Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the Investors page of Emergent’s website.

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn , X , Instagram , Apple Podcasts and Spotify .

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
[email protected]

Media Contact:
Assal Hellmer
Vice President, Communications
[email protected]